'Unique Oncology Platform': Gilead (GILD) Earns Two Upgrades After Beat-and-raise Quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Gilead Sciences (GILD) PT Raised to $86 at Jefferies
October 28, 2022 8:59 AM EDTJefferies analyst Michael Yee raised the price target on Gilead Sciences (NASDAQ: GILD) to $86.00 (from $78.00) while maintaining a Buy rating following results.
The analyst commented, "GILD put up a good Q across the board and esp strong Veklury Covid quarter... More
Gilead Sciences (GILD) PT Raised to $87 at JPMorgan
October 28, 2022 7:58 AM EDTJPMorgan analyst Chris Schott raised the price target on Gilead Sciences (NASDAQ: GILD) to $87.00 (from $80.00) while maintaining a Overweight rating.... More
Gilead Sciences (GILD) PT Raised to $75 at Wells Fargo
October 28, 2022 7:27 AM EDTWells Fargo analyst Mohit Bansal raised the price target on Gilead Sciences (NASDAQ: GILD) to $75.00 (from $74.00) while maintaining a Equal Weight rating.... More
Gilead Sciences (GILD) PT Raised to $82 at RBC Capital
October 28, 2022 6:13 AM EDTRBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $82.00 (from $79.00) while maintaining a Outperform rating.... More
